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Abstract 
Much of what we understand about heterochromatin formation in mammals has been 
extrapolated from forward genetic screens for modifiers of position-effect variegation 
(PEV) in the fruit fly Drosophila melanogaster. The recent identification of the HUSH 
(Human Silencing Hub) complex suggests that more recent evolutionary developments 
contribute to the mechanisms underlying PEV in human cells. Although HUSH-
mediated repression also involves heterochromatin spreading through the reading and 
writing of the repressive H3K9me3 histone modification, clear orthologues of HUSH 
subunits are not found in Drosophila but are conserved in vertebrates. Here we 
compare the insights into the mechanisms of PEV derived from genetic screens in the 
fly, the mouse and in human cells, review what is currently known about the HUSH 
complex, and discuss the implications of HUSH-mediated silencing for viral latency. 
Future studies will provide mechanistic insight into HUSH complex function and reveal 
the relationship between HUSH and other epigenetic silencing complexes. 
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Introduction 
As a result of the many genome sequencing projects undertaken over the past two 
decades, we now have a detailed understanding of the precise nature of the genetic code that 
holds the information required to build a biological machine as complex as the human body. 
However merely cataloguing the exact sequence of the millions of the DNA bases A, C, G 
and T does not equate to being able to understand how multicellular organisms function, as 
this genetic information must clearly be interpreted quite differently to enable the functions 
of all the different cell types.  
The DNA in the nucleus of eukaryotic cells is found in complex with proteins called 
histones, which together form a structure known as chromatin. The basic functional unit of 
chromatin is the nucleosome, consisting of 147 base pairs of DNA wrapped around two 
copies of each of the histones H2A, H2B, H3 and H4. Histones serve a dual role. First, they 
provide an essential role in the compaction of DNA, enabling approximately two metres of 
DNA to fit inside the nucleus of a human cell which has a diameter of around just ten 
microns across. Second, the structure of the chromatin fibre regulates the accessibility of the 
DNA to the plethora of factors that regulate all aspects of DNA metabolism, including gene 
expression, DNA replication and the repair of DNA damage. Therefore the expression of 
genetic information does not depend solely on the DNA sequence itself, but also upon the 
composition and activity of a myriad of chromatin-associated proteins. 
Histone proteins can be post-translationally modified, and the exact nature and 
position of these modifications has dramatic consequences for chromatin function [1]. These 
marks either exert their effects directly, altering histone-histone or histone-DNA interactions 
to produce a change in nucleosomal architecture [2], or indirectly by serving as a docking site 
for chromatin remodelling enzymes [3]. The various histone modifications are recognised by 
distinct protein machineries, and hence define distinct biological entities [4]. A variety of 
protein domains have now been characterised that act as epigenetic ‘readers’ by specifically 
recognising modified histones, such as the chromodomain that binds methylated lysine 
residues [5], and the bromodomain that binds acetylated lysine residues [6]. Chromatin 
binding proteins can possess multiple such domains, leading to the attractive idea of a 
‘histone code’ in which a particular combination of histone marks could be interpreted to 
produce a unique biological outcome [7].  
3 
 
In all higher eukaryotic organisms, a large fraction of the genome is packaged into an 
inactive form known as heterochromatin. In contrast with active euchromatin, 
heterochromatin is typically characterised as being highly condensed, gene-poor and less 
transcriptionally active. These two chromatin states were originally distinguished on the basis 
of differential cytological staining [8], but it is now clear that they represent two distinct 
biochemical entities. Euchromatin is normally associated with high levels of histone 
acetylation, as well as marks such as methylated lysine 4 of histone H3 which are found 
across active chromatin [9]. In contrast, heterochromatin is associated with low levels of 
histone acetylation and high levels of tri-methylated lysine-9 of histone H3 (H3K9me3). 
These modifications are dynamically deposited and removed by histone-modifying enzymes. 
In the case of H3K9me3, SET domain-containing proteins such as SUV39H1 and SETDB1 
function as epigenetic writers by depositing the methyl mark [10], while the Jumonji-domain 
containing family of demethylases act as epigenetic erasers by removing the methyl mark 
[11].   
Our knowledge on the mechanisms that regulate heterochromatin through the 
repressive H3K9me3 histone modification has come from the study of so-called 
“chromosomal position effects” [12], which are the main focus of this review. Position 
effects refer to the differences in expression observed when an identical gene is positioned at 
different sites in the genome. The expression level of reporter genes varies widely depending 
on the specific site of integration, with – broadly speaking – integration into euchromatin 
resulting in strong expression and integration into heterochromatin resulting in transcriptional 
repression [13]. The identities of the genes responsible for heterochromatin-mediated position 
effects have been largely studied through forward genetic screens in lower organisms. In the 
following sections we summarise the insights derived from these screens and consider their 
relevance to heterochromatin formation in man. We then focus on an analogous screen that 
we recently carried out in human cells which identified a novel epigenetic repressor complex, 
HUSH, thereby suggesting a novel route to heterochromatin formation in mammalian cells. 
 
Forward genetics screens in Drosophila identify modifiers of position-effect variegation 
Our understanding of the mechanisms of heterochromatin formation in higher 
eukaryotes is predominantly derived from classic forward genetic screens in the fruit fly 
Drosophila melanogaster for modifiers of position-effect variegation. In Drosophila this has 
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been studied extensively using the white gene. The white gene encodes a transporter which is 
required for the correct deposition of the pigments that give the Drosophila eye its 
characteristic red colour. When expressed normally in a euchromatic environment, the white 
gene is expressed, resulting in red pigment deposition. However, when placed into a 
heterochromatic environment, epigenetic silencing of the white gene leads to loss of pigment 
deposition and a mutant white eye phenotype [14]. The silencing observed is variable and 
only occurs in a proportion of the cells of the eye, resulting in patches of red and white colour 
– the so-called ‘variegated’ phenotype (Figure 1).  
A particularly well-studied example is the Inversion(1)-white-mottled-4 (w
m4
) allele, 
where the white gene is subject to silencing as a result of an inversion that places it into the 
vicinity of heterochromatin formed at the border of the nucleolus organiser [15]. This and 
other such indicator strains allowed the development of forward genetic screens to identify 
dominant mutations in the genes that were required for heterochromatin-induced epigenetic 
silencing. Flies can be screened for mutations that either suppress silencing of the white gene, 
resulting in a reversion to a red eye phenotype, or for mutations that enhance silencing of the 
white gene, resulting in a more complete white eye phenotype (Figure 1). Overall, around 
140 such suppressors of variegation (termed Su(var)) and 230 enhancers of variegation 
(E(var)) have been identified to date, with the molecular identities of approximately 30 genes 
characterised [16]. 
The study of two Su(var) genes in particular has formed the foundation for much of 
our present understanding of heterochromatin. Su(var)2-5 encodes the heterochromatin-
associated protein HP1a (heterochromatin protein 1a) which contains an N-terminal 
chromodomain and a C-terminal chromoshadow domain [17]. Su(var)3-9 encodes the 
SU(VAR)3-9 protein which contains an N-terminal chromodomain and a C-terminal SET 
domain [18]. The latter endows the protein with histone lysine methyltransferase (HKMT) 
activity, which is specifically targeted towards lysine 9 of histone H3 (H3K9) [19, 20]. Both 
HP1a and SU(VAR)3-9 localise to pericentromeric heterochromatin and associate with each 
other [20, 21], suggesting that they form a core heterochromatin complex. Molecular analysis 
of the functions of these proteins suggests a ‘read-write’ mechanism for the propagation of 
heterochromatin and PEV. The H3K9me2/3 mark deposited by SU(VAR)3-9 forms a 
docking site specifically recognised by the chromodomain of HP1a [22]. The N-terminal 
region of SU(VAR)3-9 binds the chromoshadow domain of HP1a, thereby stabilising the 
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interaction between HP1a and H3K9me2/3 and allowing the further deposition of 
H3K9me2/3 [23].   
Although this may represent a dominant mechanism at pericentromeric 
heterochromatin, the role of HP1a and SU(VAR)3-9 in heterochromatin-mediated silencing 
elsewhere in the genome is less prominent. For example, HP1α mutations have no effect on 
transgenes integrated in telomeric heterochromatin [24], and repression of reporters 
integrated along the Drosophila fourth chromosome are unaffected by mutations in Su(var)3-
9 but instead are de-repressed by mutations in the gene encoding dSETDB1, another H3K9 
lysine methyltransferase [25–27]. Distinct sets of proteins might therefore be required for 
heterochromatin-mediated silencing in different heterochromatin environments. Indeed 
modifiers of position-effect variegation can be split into distinct groups in terms of their 
ability to affect silencing at different heterochromatic domains [28, 29]. 
 
An analogous forward genetic screen identifies modifiers of position-effect variegation 
in the mouse 
Although the underlying molecular mechanisms are not as well understood in 
mammalian genomes as they are in Drosophila, similar position-effects are at work. The best 
evidence for this comes from an elegant recent study from the van Steensel laboratory [13]. 
By mapping the integration site for thousands of reporters in mouse embryonic stem (ES) 
cells and then correlating genomic position with expression level as measured by RNA-seq, 
the authors revealed that the identical gene sequence can exhibit ~1000-fold difference in 
expression depending on the specific site of genomic integration. An important goal, 
therefore, is to understand the molecular mechanisms involved and to identify the genes 
responsible.  
To this end, the laboratory of Emma Whitelaw have carried out a large-scale genetic 
screen analogous to the Drosophila PEV screens in the mouse, with the aim of clarifying the 
mechanism of epigenetic gene silencing in mammals [30]. This screen was performed using a 
mouse strain harbouring a multicopy GFP transgene integrated on chromosome 1 [31]. The 
GFP reporter is under the control of an α-globin promoter and enhancer, thereby directing 
GFP expression to erythrocytes. This reporter shows a variegated pattern of expression, with 
only ~55% of erythrocytes expressing GFP as measured by flow cytometry [30]. To identify 
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genes that affect the epigenetic silencing at this locus, a classical forward genetic screen was 
performed. Male mice homozygous for the GFP transgenes were subjected to N-ethyl-N-
nitrosourea (ENU) mutagenesis and G1 offspring analysed for changes in the pattern of GFP 
expression by flow cytometry, looking for mutations that either decrease or increase the 
degree of epigenetic silencing (analogous to the Su(var) and E(var) mutations respectively in 
Drosophila) (Figure 2).    
Of the 4000 G1 offspring screened, 40 strains displayed changes in GFP expression as 
a result of heritable, dominant-acting mutations termed Mommes (modifiers of murine 
metastable epialleles) [32]. Most of the mutations that cause the variegated phenotype in 
these Momme strains have been identified and indeed the majority map to genes encoding 
known epigenetic modifiers. These include the DNA methyltransferases Dnmt1 and Dnmt3b 
[33, 34], the histone deacetylase Hdac1 [30, 31], the chromatin-remodelling factors Smarca5 
[30, 33], Smarcc1, Pbrm1, and Baz1b [31, 32], the transcriptional regulator Trim28 [35], the 
transcription factor Klf1 [36], and the histone methyltransferases Suvar39h1 and Setdb1 [32]. 
Importantly the screens have also identified some novel components of the epigenetic 
machinery, namely Smchd1 [37], Rlf [38] and D14Abb1e [39] (the murine orthologue of 
FAM208A or TASOR in humans). 
Although there is significant overlap between the genes identified as modifiers of 
PEV in Drosophila and the Momme mutations identified in the mouse, comparing these two 
datasets does suggest some differences between the mechanisms of heterochromatin 
formation in the fruit fly as compared with mammalian cells. Several components in 
particular that were identified in the mouse do not have orthologues in Drosophila. These 
include the DNA methyltransferases Dnmt1 and Dnmt3b [12] and Smchd1 (structural-
maintenance-of-chromosomes hinge domain containing 1), a previously uncharacterised 
protein shown to have a role in the maintenance of X inactivation and the hypermethylation 
of CpG islands associated with the inactive X [37]. These data suggest that an extra layer of 
transgene silencing exists in mammalian cells that involves the deposition and maintenance 
of DNA methylation, which is sparse in Drosophila [40]. An alternative possibility is that the 
multicopy reporter installed at a single location on chromosome 1 in the mouse screens may 
not be fully representative of all heterochromatic loci across the mouse genome.  
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The near-haploid KBM7 cell line permits forward genetic screens in cultured human 
cells 
The genes involved in position-effect variegation in man are poorly defined, and this 
is largely due to the difficulty in performing analogous forward genetic screens in cultured 
human cells. However a major recent advance in the field of experimental genetics has been 
the identification and derivation of a number of haploid or near-haploid mammalian cell lines 
[41–44]. In a normal diploid human cell disruption of one allele of a gene is likely to have 
little or no phenotypic consequence, owing to compensatory gene expression from the second 
wild-type allele. This is a major barrier for forward genetic screens, as bi-allelic mutation of 
genes – at least prior to the advent of CRISPR/Cas9-technology [45] – has been difficult to 
achieve through chemical or insertional mutagenesis. In contrast, gene inactivation on a 
haploid background results in a total loss of gene function, thereby enabling classic forward 
genetic analysis. 
Initially it was the pioneering work of the Brummelkamp laboratory that showed that 
the near-haploid human KBM7 cell line could be used to carry out forward genetic screens in 
cultured human cells [42] (Figure 3). The KBM7 cell line was originally derived from a 
patient with chronic myeloid leukaemia [41], and possesses just a single copy of each 
chromosome except chromosome 8 and the sex chromosomes [46]. Insertional mutagenesis 
with a gene-trap retroviral vector can therefore be used to create a library of knockout cells, 
from which mutant cells displaying the phenotype of interest can be selected. Mapping the 
integration sites of the gene-trap vector in the selected cells – a process which is greatly 
facilitated by the power of next-generation sequencing [47] – then reveals the inactivated 
genes which are involved in the process under investigation. Since then a fully-haploid, 
fibroblast-like derivative of KBM7 called HAP1 has been generated [48, 49], and two groups 
have reported the derivation of haploid murine ES cells [43, 44] which have also been used 
successfully for forward genetic screens [50, 51].   
 
The HUSH complex mediates position-effect variegation in human cells 
We recently exploited the power of non-lethal haploid genetic screens in KBM7 cells 
[52, 53] to directly examine the genetic basis of position-effect variegation in human cells 
[54]. The experimental design was directly analogous to the screens in Drosophila and the 
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mouse described above. The starting point was a green fluorescent protein (GFP) reporter 
gene inserted into a heterochromatic environment that was subject to epigenetic silencing, 
and, following insertional mutagenesis, we selected for mutants in which this epigenetic 
repression was relieved. A major advantage of performing the screen in cultured cells as 
opposed to a whole organism was that fluorescence-activating cell sorting (FACS) could be 
used to isolate large numbers of cells expressing defined levels of expression of the GFP 
reporter. In practice, near-haploid KBM7 cells were transduced with a lentiviral vector which 
inserted a GFP reporter construct across the genome. All the cells which had become GFP
dim 
as a result of epigenetic silencing were collected by FACS, and, following insertional 
mutagenesis, mutants were isolated that had reverted to a GFP
bright 
phenotype (Figure 4). In 
this way the screen was designed to examine the dominant mechanism of position-effect 
variegation across the genome, rather than studying heterochromatin regulation at a single 
reporter integration site. 
 The haploid screen identified four genes as being essential for reporter silencing: 
SETDB1, a histone lysine methyltransferase, and three less-well characterised genes, 
FAM208A (for which we proposed the new name TASOR, for transgene activation 
suppressor), MPHOSPH8 (encoding M-phase phosphoprotein 8 (MPP8), a chromodomain-
containing protein) and PPHLN1 (encoding Periphilin). Subsequent proteomic and 
biochemical analysis revealed that TASOR, MPP8 and Periphilin exist together in a complex 
which we named the Human Silencing Hub (HUSH) complex. There were two initial clues as 
to the likely function of HUSH: (1) MPP8 had previously been shown to associate with 
SETDB1 [55], a histone methyltransferase responsible for depositing the repressive histone 
mark H3K9me3 [56], and (2) the chromodomain of MPP8 had already been shown to bind 
H3K9me3 [55, 57, 58]. The possibility that HUSH could both bind (through the MPP8 
chromodomain) and deposit (through the recruitment of SETDB1) the repressive H3K9me3 
modification suggested that the role of the HUSH complex may be in the ‘spreading’ of 
H3K9me3 from existing heterochromatin across the newly-integrated reporter construct to 
mediate epigenetic repression.    
 
The HUSH complex mediates heterochromatin spreading through H3K9me3  
 A key feature of the HUSH-mediated silencing of integrated transgenes is that not all 
transgenes are subject to this phenomenon. Although we found HUSH to be active on both 
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viral and non-viral transgenes driven by multiple different promoters, we observed that only a 
fraction of the integrated GFP constructs in each case exhibited HUSH-mediated repression 
[54]. This finding suggests that transgenes are not directly targeted by HUSH in a DNA 
sequence-specific manner, since such a mechanism would presumably result in the silencing 
of all transgene integrations. Rather it seems that the position of integration into the genome 
is critical in determining whether HUSH-mediated silencing takes place. By mapping the 
genomic integration sites of the transgenes that were subject to silencing, we observed a 
striking correlation between high levels of H3K9me3 in the vicinity of the integration site and 
HUSH-mediated repression [54].  
What are the implications of this result for the mechanism of HUSH-mediated 
silencing? Seemingly the HUSH complex is normally bound at H3K9me3-rich regions of the 
genome, and, upon integration of an active transgene nearby, HUSH facilitates the spreading 
of H3K9me3 to form new heterochromatin across the transgene and mediate transcriptional 
silencing. Such a mechanism would explain how transgenes landing into euchromatic regions 
lacking H3K9me3 are immune from the effects of HUSH. Even after repression is initially 
established, however, there is an ongoing requirement for HUSH to maintain the state of 
epigenetic repression. This suggests that there must be competing mechanisms at work that 
function to reverse the heterochromatic state installed through HUSH activity. This could be 
a passive process of progressive dilution of H3K9me3-marked histones through cell division, 
or an active process involving a competing H3K9me3 demethylase. In this regard it would be 
interesting to explore whether loss of  Jumonji domain demethylases (such as KDM4D which 
is known to erase the H3K9me3 mark [59]) would act as enhancers of transgene silencing in 
human cells. Interestingly in the fission yeast Schizosaccharomyces pombe two recent studies 
have demonstrated that active H3K9 demethylation by the putative Jumonji demethylase 
Epe1 [60] can counteract silencing resulting from recruitment of the single yeast H3K9 
methyltransferase Clr4, and that this prevents the stable maintenance of a heterochromatic 
domain [61, 62]. The balance between HUSH and SETDB1-mediated deposition of 
H3K9me3 and active demethylation could therefore also be important for preventing the 
aberrant spread of heterochromatin in human cells.  
  
How does HUSH-mediated transgene silencing compare with KAP1-mediated retroviral 
silencing? 
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Integrated retroviral DNA is potently silenced in murine ES cells [63], in a process 
mediated by the key co-repressor KAP1 (also known as TRIM28 or TIF1β) [64]. KAP1, 
through its RBCC domain [65], interacts with members of the KRAB (Krüppel-associated 
box) domain-containing zinc finger protein (KRAB-ZFP) family of transcription factors [66]. 
These KRAB-ZFP transcription factors mediate the specific recognition of the viral primer 
binding site (PBS) of individual retroviruses. In the case of murine leukaemia virus (MLV), 
for example, ZFP809 bridges the viral DNA to the KAP1 co-repressor to mediate retroviral 
silencing [67]. Although the downstream events that lead to epigenetic repression of the 
integrated provirus are not fully defined, there is a central role for the H3K9 
methyltransferase SETDB1 [68, 69], which is a binding partner of KAP1 [56]. SETDB1 
recruitment leads to the deposition of the repressive H3K9me3 histone modification across 
the provirus and silencing of viral gene expression. There may also be an important role for 
DNA methylation [70], and the histone variant H3.3 [71]. 
A central feature of this model is that a different KRAB-ZFP protein would be 
required to specifically bind each different class of retroviral element. This is supported by 
the rapid expansion of the KRAB-ZFP gene family to over 350 members in humans, 
suggesting an evolutionary ‘arms race’ in which new KRAB-ZFP evolve to combat fresh 
retroelements as they emerge [72]. The best experimental support comes from an elegant 
recent study using a trans-chromosomic mouse ES cell line harbouring a copy of human 
chromosome 11 [73]. In the murine cellular environment, the primate-specific SINE-VNTR-
Alu (SVA) and Long Interspersed Nuclear Element-1 (L1) retroelements are derepressed and 
become aberrantly transcribed. By screening a series of candidate human KRAB-ZFP 
proteins, the authors showed that expression of ZNF91 and ZNF93 could restore the 
recruitment of KAP1 to these elements and re-install transcriptional repression [73].  
So how does this mechanism of KAP1-mediated viral silencing in ES cells compare 
to HUSH-mediated silencing of transgenes? Although there are clear similarities between the 
two processes, such as the shared requirement for the histone methyltransferase SETDB1 and 
the H3K9me3 histone mark, the key difference is that KAP1 mediates sequence-specific 
repression of retroelements, whereas HUSH mediates position-specific repression of any 
integrated transgene (Figure 5, A and C). This is perhaps best illustrated when considering 
what happens to integrated viruses following transduction of ES cells as compared with 
commonly used cancer cell lines. In the latter, reporter gene expression is extremely stable; 
the expression observed two days after infection is then maintained for weeks. The initial, 
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HUSH-mediated repression of viruses landing in repressed heterochromatin results in the 
population of ‘dim’ cells, but the ‘bright’ cells containing integrations into euchromatic 
environments remain stably expressed (Figure 5B). In ES cells, however, all of the 
integrations are rapidly subject to KAP1-mediated repression and become silenced over the 
course of a few days (Figure 5D). Therefore, the HUSH complex mediates the epigenetic 
silencing of transgenes integrating into pre-existing heterochromatin, whereas in ES cells 
KAP1 specifically silences viral integrations regardless of their position in the genome. In 
contrast to the spreading of pre-existing heterochromatin mediated by HUSH, KAP1 appears 
to nucleate the de novo formation of heterochromatin at specific genomic sites to which it is 
recruited through a KRAB-ZFP protein. 
 
How has the HUSH complex evolved? 
Why did the Drosophila screens for modifiers of position-effect variegation not 
identify HUSH? The answer is immediately apparent when examining the evolutionary 
conservation of the HUSH proteins: clear orthologues of HUSH complex subunits are not 
found in flies, but are only conserved from fish to humans. This raises another question, why 
has the HUSH complex evolved more recently? Although further work will be required to 
understand why this might be, it is clear that HUSH plays a critical role in higher organisms, 
as both TASOR [39] and Periphilin [74] are indispensable for murine development. Loss of 
HUSH subunits results in decreased H3K9me3 at hundreds of genomic loci [54], and so the 
HUSH complex may therefore have an essential role in heterochromatin maintenance in the 
early embryo, or may play a critical role in directing normal gene expression programs during 
early development. Furthermore, HUSH subunits are expressed in ES cells [75], and TASOR 
may itself be a direct target of the key pluripotency regulator Oct4 [76, 77]. Therefore, 
determining how loss of HUSH affects the ES cell transcriptome may be informative in 
further understanding its physiological role.  
Although it is clear why the Drosophila PEV screens did not identify HUSH complex 
components, a more puzzling question is why our haploid genetic screen did not identify the 
canonical heterochromatin regulators such as HP1 and SUV39H1 that are critical for PEV in 
the fly. This may simply be a technical issue, as our haploid screen may not have reached 
saturation and hence HP1 and SUV39H1 could be false-negatives. Alternatively functional 
redundancy between the three human HP1 isoforms or between the highly homologous 
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SUV39H1 and SUV39H2 might prevent individual knockouts of these genes from generating 
a phenotype. It would therefore be interesting to examine the potential for cross-talk between 
HUSH and other heterochromatin regulators such as HP1 and SUV39H1, and to establish 
how the different systems divide the labour at different genomic sites or in different cell 
types.  
 
The HUSH complex can mediate the epigenetic repression of integrated viruses 
Although transgenesis is not a natural process, position-effect variegation is relevant 
in the context of retroviral infection, where viral DNA encoding active genes is integrated 
into the host genome. The integration preferences of human immunodeficiency virus type 1 
(HIV-1) [78–81] and other retroviruses [82, 83] are well-studied and, although there is a 
strong bias towards integration into active transcriptional units, a significant minority of 
integrations occur into heterochromatin. We found evidence for HUSH-mediated silencing of 
both HIV-1 and murine leukaemia virus (MLV) LTR promoters through H3K9me3 [54], 
raising the question of whether HUSH-mediated silencing of retroviruses integrated in 
heterochromatin could be an important factor in the establishment or maintenance of viral 
latency. In the case of HIV-1, although highly active antiretroviral therapy (HAART) can 
reduce plasma HIV-1 below clinically detectable levels in AIDS patients, cessation of 
treatment leads to a rebound in plasma viraemia owing to viral reactivation from latent 
reservoirs in resting CD4
+
 T cells [84]. A cure for HIV-1 infection will therefore require a 
pharmacological strategy to purge this latent pool. Depletion of HUSH subunits can result in 
reactivation of silent HIV-1 reporter viruses in cell culture models [54]. However, the 
dominant viral integration sites mapped in patients with persistent HIV infection are not 
seemingly enriched in proximity to heterochromatic regions [85, 86], although it has been 
questioned whether the proviruses identified in these studies are capable of lytic reactivation 
[87, 88]. It will therefore be important to determine the clinical relevance of HUSH-mediated 
silencing in HIV-1 pathogenesis, and the utility of HUSH inhibition in purging the latent pool 
of HIV-1 that persists in the face of antiretroviral therapy.  
HUSH may also be required for the silencing and maintenance of latency of non-
integrating viruses, such as the clinically important herpesviruses. Human cytomegalovirus 
(HCMV), for example, is a highly prevalent human pathogen that mediates life-long infection 
through the establishment of latency in haematopoietic stem cells [89]. Chromatinisation of 
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incoming viral DNA occurs minutes after initial infection [90], and, in latently infected cells, 
the ~250 kb HCMV genome is stably maintained as a non-replicating episome. This latent 
state is primarily maintained through epigenetic mechanisms, with the critical major 
intermediate early gene promoter coated with H3K9me3 and bound by HP1 [91]. Myeloid 
differentiation triggers lytic reactivation with loss of repressive histone modifications, 
eviction of HP1, and installation of active histone marks to facilitate lytic gene expression 
[92]. KAP1 was recently reporter to play a key role in HCMV latency, by directing the 
recruitment of SETDB1 to the viral genome to deposit H3K9me3 [93], and has also been 
implicated in the replication of both Epstein-Barr virus (EBV) [94] and Kaposi’s sarcoma-
associated herpesvirus (KSHV) [95, 96]. Whether KAP1 and HUSH co-operate in the 
recruitment of SETDB1 to silence these viral genomes remains to be determined.  
 
Understanding HUSH complex function: future challenges 
A key challenge for future studies will be the dissection of the molecular details of 
HUSH-mediated silencing (Figure 6). In particular, the specific roles of TASOR and 
Periphilin in the silencing process remain unclear. If MPP8 alone can both recognise 
H3K9me3 through its chromodomain [57, 58, 97], and bind SETDB1 [55] to direct further 
H3K9me3 deposition, then a read-write mechanism for heterochromatin spreading would 
seemingly need just these two components. However, the critical requirement for both 
TASOR and Periphilin for HUSH function [54] implicates further complexities beyond this 
simplistic model. TASOR is of particular interest due to its large size (1670 amino acids), yet 
lack of any discernible domains. The only feature currently annotated is an N-terminal 
‘domain of unknown function’ (DUF3715), but its identity and role in HUSH-mediated 
repression is unknown. Periphilin is the smallest of the HUSH subunits, but also has no 
clearly discernible domains and indeed is predicted to be largely unstructured [98, 99].  
The ability to maintain stable transgene expression is important in biotechnological 
applications and in gene therapy. While the development of small molecule inhibitors of 
HUSH or SETDB1 would be one strategy to prevent the invasion of heterochromatin into 
therapeutic transgenes, a more attractive option would be the identification of insulator 
sequences that can halt the HUSH-mediated spreading of H3K9me3. By far the best 
characterised insulator is HS4, identified through the study of gene regulation at the chicken 
β-globin locus, which can act as a ‘barrier insulator’ to prevent the spread of heterochromatin 
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[100]. The possibility of flanking therapeutic transgenes with HS4 or other such insulator 
sequences which might render active genes immune to HUSH-mediated 
heterochromatinisation might be an attractive option to mitigate unwanted silencing resulting 
from position effects.  
 
Conclusion and Outlook 
Recent advances in experimental human genetics now allow the re-evaluation of old 
questions that were previously only amenable to genetic analysis in lower eukaryotes. We 
exploited the near-haploid KBM7 cell line to identify genes involved in position-effect 
variegation in human cells, a phenomenon that has been widely studied in the fly. The 
haploid screen identified HUSH, an epigenetic repressor complex composed of three 
subunits, TASOR, MPP8 and Periphilin. The Drosophila genome does not possess clear 
orthologues of these genes, suggesting that HUSH represents a novel route to H3K9me3-
mediated heterochromatin formation in mammalian cells. A central feature of HUSH function 
is that it appears to mediate the spreading of pre-existing heterochromatin through the reading 
and writing of H3K9me3, and hence is only responsible for the silencing of active transgenes 
when integrated into heterochromatic genomic loci.  
Much further work will be required to understand in molecular detail the mechanistic 
basis of HUSH function, and to determine why it is critical for early mammalian 
development. Another key question concerns the relationship between HUSH and other 
silencing systems in the cell: for example, does HUSH cooperate with HP1 and SUV39H1 at 
certain sites or in certain cell types, or do they act independently of one another at discrete 
genomic loci? Finally, it is possible that modulation of HUSH function might have clinical 
applications. Insulating therapeutic transgenes from HUSH-mediated heterochromatin 
invasion could be beneficial in gene therapy, while pharmacological inhibition of HUSH 
function may provide a strategy for reactivating latent proviruses integrated at 
heterochromatic loci. A greater understanding of the molecular mechanisms of HUSH 
function will be essential before the feasibility of these applications can be properly assessed. 
More broadly, haploid genetic screens in human cells may now permit the re-evaluation of 
other pathways that could previously only be interrogated genetically in model eukaryotic 
organisms. 
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Figure Legends 
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Figure 1. Forward genetic screens for modifiers of position-effect effect in the fruit fly 
Drosophila melanogaster.  
Epigenetic silencing of the white gene occurs when it is placed into a heterochromatic 
environment, resulting in a variegated phenotype in the Drosophila eye. Following random 
mutagenesis, files can be screened for dominant mutations which either suppress variegation, 
resulting in derepression of the white gene and reversion to a red-eye phenotype, or mutations 
which enhance variegation, resulting in a more complete white-eye phenotype.  
 
Figure 2. Forward genetic screens for modifiers of transgene silencing in the mouse. 
The Momme mouse line harbours a mutilcopy GFP transgene on chromosome 1 which is 
subject to variable epigenetic silencing, resulting in GFP expression in approximately 55% of 
erythrocytes. Following random mutagenesis, mice can be screened for mutations which 
either increase or decrease the proportion of GFP
+
 cells. Thus far, more than 40 strains which 
show significant changes in GFP expression have been characterised. 
 
Figure 3. Forward genetic screens in haploid human cells. 
The human KBM7 cell line, isolated from a patient with chronic myeloid leukaemia, is highly 
unusual in that it is haploid for all chromosomes with the exception of chromosome 8 and the 
sex chromosomes. Mutagenesis of this cell line using a gene-trap retrovirus therefore creates 
a library of total gene knockouts, which can then be screened for mutants which are defective 
in the process under investigation. The simplest way to do this is to apply a lethal insult (left 
side), whereby the rare resistant cells which grow out harbour mutations in the killing 
pathway, although a FACS-based method for the positive selection of cells which display 
altered levels of a cell surface protein or of a genetically-encoded fluorescent reporter is more 
widely applicable to the study of diverse cellular processes (right side). Finally, the sites of 
integration of the gene-trap vector are mapped in the selected cells to reveal the disrupted 
genes responsible for the mutant phenotype. 
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Figure 4. A haploid genetic screen to identify genes required for transgene silencing in 
human cells. 
A: Near-haploid KBM7 cells were transduced with a reporter construct expressing GFP, 
resulting in the integration of the GFP reporter across the genome. Due to chromosomal 
position effects this results in a wide range of GFP levels, with a minority of integrations 
occurring in repressive heterochromatin leading to a GFP
dim
 phenotype. 
B: To identify the genes responsible for epigenetic suppression of the GFP reporter, the 
GFP
dim
 cells were isolated by FACS, mutagenised with a gene-trap retrovirus, and then rare 
mutant GFP
bright
 cells in which derepression of the GFP reporter was lost isolated by FACS. 
Comparing the gene-trap integrations sites in the GFP
bright
 cells with those in the unselected 
mutant library identified four genes that were responsible for epigenetic repression of the 
transgene. 
   
Figure 5. Contrasting the mechanisms of heterochromatin formation by KAP1 and the 
HUSH complex.  
A and B: Spreading of pre-existing heterochromatin by the HUSH complex. The HUSH 
complex is localised at H3K9me3-rich regions of the genome through the chromodomain of 
MPP8, where, through the recruitment of SETDB1, it mediates the spreading of the 
repressive H3K9me3 modification to mediate the repression of transgenes integration into 
heterochromatin (A). In human cancer cell line such as HeLa, HUSH-mediated repression of 
integrated transgenes results in a spread of reporter gene expression, which is then stably 
maintained over time (B).  
C and D: De novo heterochromatin formation by KAP1 mediates retroviral silencing in ES 
cells. Specific targeting of a retroelement by a KRAB-ZFP protein results in the recruitment 
of KAP1 and SETDB1 and silencing through the deposition of H3K9me3 (C). KAP1 is able 
to target the integrated proviral DNA at all genomic loci, resulting in the silencing of reporter 
gene expression in all cells over the course of a few days (D).  
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Figure 6. Molecular view of the HUSH complex subunits.   
Schematic representations of the domain architecture of the three HUSH subunits and 
SETDB1 are shown. Aside from the chromodomain of MPP8 and the catalytic SET domains 
of SETDB1, little is currently known about the function of the other regions of the four 
proteins.  
